ReviewNature reviews. Clinical oncology2010
Importance of tumor load in the sentinel node in melanoma: clinical dilemmas.
Review in Nature reviews. Clinical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04529915 (Multicenter Clinical Research for Early Diagnosis of Lung Cancer Using Blood Plasma), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Multicenter Clinical Research for Early Diagnosis of Lung Cancer Using Blood Plasma
Who cites it
13 citing papers in PubMed.
- Independent Dutch Validation Study of CP-GEP (Merlin Assay) for the Prediction of Nodal Metastasis and Long-Term Outcome in Patients with Primary Cutaneous Melanoma.Annals of surgical oncology · 2026Article
- Induction of potassium channel regulator KCNE4 in a submandibular lymph node metastasis model.Scientific reports · 2022Article
- Current management of melanoma patients with nodal metastases.Clinical & experimental metastasis · 2022Review
- Melanoma-derived small extracellular vesicles induce lymphangiogenesis and metastasis through an NGFR-dependent mechanism.Nature cancer · 2021Article
- Inactivation of EMILIN-1 by Proteolysis and Secretion in Small Extracellular Vesicles Favors Melanoma Progression and Metastasis.International journal of molecular sciences · 2021Article
- An evidence-based approach to positive sentinel node disease: should we ever do a completion node dissection?Melanoma management · 2019Review
- The influence of tumour-derived extracellular vesicles on local and distal metastatic dissemination.Molecular aspects of medicine · 2018Review
- Lymph Node Micrometastases and In-Transit Metastases from Melanoma: In Vivo Detection with Multispectral Optoacoustic Imaging in a Mouse Model.Radiology · 2016Article
- Gene expression analyses of primary melanomas reveal CTHRC1 as an important player in melanoma progression.Oncotarget · 2016Article
- The interplay between hypoxia, endothelial and melanoma cells regulates vascularization and cell motility through endothelin-1 and vascular endothelial growth factor.Carcinogenesis · 2014Article
- SLN melanoma micrometastasis predictivity of nodal status: a long term retrospective study.Journal of experimental & clinical cancer research : CR · 2013Article
- Sentinel lymph node biopsy for high-risk cutaneous squamous cell carcinoma: clinical experience and review of literature.World journal of surgical oncology · 2011Review
- Controversies in the diagnosis and treatment of early cutaneous melanoma.Journal of medicine and lifeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are two hypotheses to explain melanoma dissemination: first, simultaneous lymphatic and hematogeneous spread, with regional lymph nodes as indicators of metastatic disease; and second, orderly progression, with regional lymph nodes as governors of metastatic disease. The sentinel node (SN) has been defined as the first draining lymph node from a tumor and is harvested with the use of the triple technique and is processed by an extensive pathology protocol. The SN status is a strong prognostic factor for survival (83-94% for SN negative, 56-75% SN-positive patients). False-negative rates are considerable (9-21%). Preliminary results of the MSLT-1 trial did not demonstrate a survival benefit for the SN procedure, although a subgroup analysis indicates a possible benefit. A mathematical model has demonstrated 24% prognostic false positivity. SN tumor burden represents a heterogeneous patient population and is classified most frequently with the Starz, Dewar or Rotterdam Criteria. A completion lymph-node dissection might not be indicated in all SN-positive patients. Patients classified with metastases <0.1 mm by the Rotterdam Criteria have excellent survival rates. Ultrasound-guided fine-needle aspiration cytology is emerging as a staging tool for high-risk patients, but more research is necessary before this can change clinical practice.
Indexed as
Identifiers
20567244What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.